Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.035 USD | -5.05% | -7.14% | -16.80% |
Mar. 21 | Earnings Flash (KRON) KRONOS BIO Reports Q4 Revenue $2.3M | MT |
Mar. 21 | Kronos Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.80% | 65.5M | C- | ||
-1.38% | 41.71B | B | ||
+47.70% | 41.56B | A | ||
+3.48% | 39.74B | B- | ||
-15.14% | 25.61B | C | ||
+3.46% | 24.26B | B- | ||
-23.36% | 18.55B | B | ||
-2.28% | 11.93B | C+ | ||
+25.12% | 11.93B | C+ | ||
+7.59% | 10.91B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- KRON Stock
- Ratings Kronos Bio, Inc.